Komori
Kissei Pharmaceutical (4547) · FactAnnual revenue growth, operating and ordinary lossesLatest Earnings (2026-07-31): "Other"

Decline in Operating Income, Ordinary Income and Net Income Despite Higher Revenue

First written in FY2017-Q2. 3 of 37 entries say "Advanced", first in FY2024-Q3. Latest entry: 2026-07-31.

37entries
11years
4from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2017-Q2 – FY2024-Q22016: 12017: 420172018: 420182019: 420192020: 420202021: 320212022: 420222023: 320232024: 320242025: 220252026: 52026
Same theme, other companies
Profit decline amid revenue growth, growth investment and cost burdensA theme 105 companies write about · 136 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2026: 19 of 78 companies on the "Worse" side.

32 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 105 companies compared. The sentences above are computed from all 105.
Full recordFilings, disclosures and news, newest first
  1. FY2026Annual revenue growth, operating and ordinary lossesAnnual report

    「Revenue (¥ million) 88,330 97,406 10.3 Operating income or operating loss (△) (¥ million) 5,773 △2,927 - Ordinary income or ordinary loss (△) (¥ million) 6,974 △1,162 -」

    Revenue increased 10.3%, while the company posted an operating loss of ¥2,927 million and an ordinary loss of ¥1,162 million due to a higher cost-of-sales ratio and increased selling, general and administrative expenses, mainly research and development expenses.
  2. FY2026-H1First-half operating and ordinary losses despite higher revenueAnnual report

    「Although higher revenue was secured, operating and ordinary losses were recorded due to a rise in the cost-of-sales ratio and increases in selling, general and administrative expenses, mainly research and development expenses. Meanwhile, interim net income attributable to owners of the parent increased.」

    First-half revenue was ¥45,831 million, up 7.9% year on year, while the company posted an operating loss of ¥6,837 million and an ordinary loss of ¥5,622 million. Research and development expenses increased to ¥16,328 million, but interim net income attributable to owners of the parent rose 48.3% year on year to ¥7,784 million, due to gains on the sale of investment securities and other factors.
  3. FY2025AdvancedAnnual report

    「In terms of earnings, despite an increase in selling, general and administrative expenses, mainly research and development expenses, operating income, ordinary income and net income attributable to owners of the parent increased due to higher revenue and an improved cost-of-sales ratio.」

    Driven by higher revenue and an improved cost-of-sales ratio, operating income was ¥5,773 million, ordinary income was ¥6,974 million, and net income attributable to owners of the parent was ¥11,961 million, continuing the recovery trend from the previous fiscal year.
  4. FY2025-H1First-half earnings decline despite higher revenueAnnual report

    「In terms of earnings, despite higher revenue and an improved cost-of-sales ratio, operating income, ordinary income and interim net income attributable to owners of the parent declined due to an increase in selling, general and administrative expenses, mainly research and development expenses.」

    Revenue increased 14.8% year on year, while operating income decreased 11.6%, ordinary income decreased 35.4%, and interim net income attributable to owners of the parent decreased 7.6%, resulting in lower earnings despite higher revenue.
  5. FY2024AdvancedAnnual report

    「In terms of earnings, operating income, ordinary income and net income attributable to owners of the parent increased, driven by higher revenue, an improved cost-of-sales ratio and a decrease in selling, general and administrative expenses, mainly research and development expenses.」

    The company recovered from an operating loss of ¥1,129 million to operating income of ¥4,017 million, while ordinary income recovered to ¥6,142 million, resulting in improved earnings amid higher revenue.
  6. FY2024-Q3AdvancedAnnual report

    「In terms of earnings, operating income, ordinary income and net income attributable to owners of the parent increased, driven by higher revenue, an improved cost-of-sales ratio and a decrease in selling, general and administrative expenses, mainly research and development expenses.」

    For the nine months ended Q3, revenue increased 12.1% year on year, operating income rose from ¥492 million to ¥4,164 million, ordinary income rose from ¥2,113 million to ¥6,100 million, and net income attributable to owners of the parent rose from ¥6,667 million to ¥8,337 million.
  7. FY2024-Q2Higher first-half revenue, return to operating profitability, higher ordinary income and higher net incomeAnnual report

    「In terms of earnings, operating income, ordinary income and net income attributable to owners of the parent increased, driven by higher revenue, an improved cost-of-sales ratio and a decrease in selling, general and administrative expenses, mainly research and development expenses. Gains on the sale and valuation of securities were recorded as non-operating income, while a gain on the sale of investment securities was recorded as extraordinary income.」

    First-half revenue increased 12.5% year on year, and the company swung from an operating loss of ¥625 million to operating income of ¥2,015 million. Ordinary income was ¥3,465 million, and net income attributable to owners of the parent was ¥5,678 million.
  8. FY2024-Q1Higher revenue, operating income recovery, higher ordinary income and higher net incomeAnnual report

    「Revenue (¥ million) 16,285 19,313 18.6 Operating income (¥ million) 130 1,633 - Ordinary income (¥ million) 806 2,712 236.2 Net income attributable to owners of the parent (¥ million) 1,635 3,265 99.6」

    From the revenue and earnings declines in the same period of the previous year, revenue increased 18.6%, operating income rose from ¥130 million to ¥1,633 million, ordinary income increased 236.2%, and net income attributable to owners of the parent increased 99.6%.
  9. FY2023-Q3Third-quarter revenue growth, return to operating profitability, ordinary profit growth, net profit declineAnnual report

    「In terms of earnings, despite an increase in selling, general and administrative expenses, operating income and ordinary income increased, driven by higher revenue and an improved cost-of-sales ratio. Net income attributable to owners of the parent decreased despite the recognition of a gain on the sale of investment securities.」

    For the nine months ended Q3, revenue increased 3.1%, operating income was ¥492 million, compared with an operating loss of ¥294 million in the same period of the previous year, and ordinary income increased 56.5%, while net income attributable to owners of the parent decreased 2.2%.
  10. FY2023-Q2First-half revenue growth, operating loss, ordinary profit decline, net profit declineAnnual report

    「Although revenue increased and the cost-of-sales ratio improved, an operating loss was recorded due in part to an increase in selling, general and administrative expenses, mainly research and development expenses, and ordinary profit declined. Net income attributable to owners of the parent also declined despite gains on sales of investment securities being recorded.」

    In the first half, revenue increased 1.5% year on year, while an operating loss of ¥625 million was recorded, ordinary profit declined 75.9% and net income attributable to owners of the parent declined 41.3%.
  11. FY2023-Q1Quarterly revenue decline, operating profit decline, ordinary profit growth, net profit declineAnnual report

    「Revenue (¥ million) 16,635 16,285 △2.1 Operating profit (¥ million) 293 130 △55.4 Ordinary profit (¥ million) 764 806 5.6 Net income attributable to owners of the parent (¥ million) 3,644 1,635 △55.1」

    In the first quarter, revenue declined 2.1%, operating profit declined 55.4% and net income attributable to owners of the parent declined 55.1%, while ordinary profit increased 5.6%.
  12. FY2022Annual revenue decline, operating loss, ordinary profit decline, net profit growthAnnual report

    「In addition to lower revenue, selling, general and administrative expenses, mainly research and development expenses, increased, resulting in an operating loss. In non-operating income and expenses, profit declined by ¥6 million from the previous fiscal year due in part to a decrease in gains on valuation of securities. Ordinary profit declined by ¥2,913 million, or 83.8%, from the previous fiscal year to ¥562 million. In extraordinary income and expenses, profit increased by ¥11,944 million from the previous fiscal year due in part to an increase in gains on sales of investment securities. As a result, income before income taxes increased by ¥9,031 million, or 120.8%, from the previous fiscal year to ¥16,507 million, and net income attributable to owners of the parent increased by ¥7,636 million, or 144.5%, to ¥12,921 million.」

    Annual revenue declined 5.3% and an operating loss of ¥1,402 million was recorded, while ordinary profit declined 83.8% and net income attributable to owners of the parent increased 144.5% due to gains on sales of investment securities.
  13. FY2022-Q3Third-quarter revenue decline, operating loss, ordinary profit decline, net profit growthAnnual report

    「In addition to lower revenue, the cost-of-sales ratio increased due to changes in the product sales mix, and selling, general and administrative expenses, mainly research and development expenses, increased. As a result, an operating loss was recorded and ordinary profit declined. Net income attributable to owners of the parent increased due in part to the recording of gains on sales of investment securities.」

    For the first 3 quarters, revenue declined 4.0%, an operating loss of ¥294 million was recorded and ordinary profit declined 70.4%, while net income attributable to owners of the parent increased 5.9% due to gains on sales of investment securities.
  14. FY2022-Q2First-half slight revenue growth, sharp operating and ordinary profit decline, net profit growthAnnual report

    「Operating profit and ordinary profit declined due to a higher cost-of-sales ratio and an increase in selling, general and administrative expenses, mainly research and development expenses. Net income attributable to owners of the parent increased due in part to the recording of gains on sales of investment securities.」

    In the first half, revenue increased 0.3% year on year, while operating profit declined 86.8% and ordinary profit declined 53.9%. Net income attributable to owners of the parent increased 28.9% due to the recording of gains on sales of investment securities.
  15. FY2022-Q1Quarterly revenue growth, operating and ordinary profit decline, net profit growthAnnual report

    「Operating profit and ordinary profit declined due to a higher cost-of-sales ratio and an increase in selling, general and administrative expenses, mainly research and development expenses. Net income attributable to owners of the parent increased due in part to the recording of gains on sales of investment securities.」

    Revenue increased 3.6% year on year, while operating profit declined 82.1% and ordinary profit declined 64.8%. Net income attributable to owners of the parent increased 111.2% due to the recording of gains on sales of investment securities.
  16. FY2021-Q3Third-quarter revenue and profit growthAnnual report

    「Although the cost-of-sales ratio increased, operating profit, ordinary profit and net income attributable to owners of the parent increased due in part to higher revenue and a decrease in selling, general and administrative expenses, mainly research and development expenses. Gains on sales of investment securities were recorded as extraordinary income.」

    For the first 3 quarters, revenue increased 7.5% year on year, operating profit increased 16.5%, ordinary profit increased 19.3% and net income attributable to owners of the parent increased 81.8%, with operating profit, ordinary profit and net profit all increasing.
  17. FY2021-Q2First-half revenue growth, operating and ordinary profit decline, net profit growthAnnual report

    「Although revenue increased, selling, general and administrative expenses declined due to lower unspent operating expenses associated with the curtailment of promotional activities, including medical information activities, and deferred timing of contract-fee payments to overseas alliance partners, partly reflecting the impact of COVID-19. However, operating profit and ordinary profit declined due in part to a higher cost-of-sales ratio. Net income attributable to owners of the parent increased due in part to the recording of gains on sales of investment securities.」

    In the first half, revenue increased 2.3% year on year, while operating profit declined 12.4% and ordinary profit declined 2.7%. Net income attributable to owners of the parent increased 104.4% due to gains on sales of investment securities.
  18. FY2021-Q1Quarterly revenue and profit declineAnnual report

    「Revenue (¥ million) 16,099 16,061 △0.2 Operating profit (¥ million) 2,061 1,633 △20.8 Ordinary profit (¥ million) 2,406 2,169 △9.9 Net income attributable to owners of the parent (¥ million) 2,012 1,725 △14.3」

    Revenue declined 0.2% year on year, operating profit declined 20.8%, ordinary profit declined 9.9% and net income attributable to owners of the parent declined 14.3%.
  19. FY2020Annual revenue decline and sharp profit declineAnnual report

    「Operating profit declined by ¥4,345 million, or 70.1%, from the previous fiscal year to ¥1,857 million. … Ordinary profit declined by ¥4,740 million, or 66.1%, from the previous fiscal year to ¥2,429 million. … Net income attributable to owners of the parent declined by ¥2,663 million, or 48.6%, from the previous fiscal year to ¥2,817 million.」

    Annual revenue declined 12.5%, operating profit declined 70.1%, ordinary profit declined 66.1% and net income attributable to owners of the parent declined 48.6%, resulting in lower revenue and a sharp profit decline.
  20. FY2020-Q3Third-quarter revenue and profit decline continuedAnnual report

    「Revenue (¥ million) 55,255 48,552 △12.1 Operating profit (¥ million) 4,970 2,739 △44.9 Ordinary profit (¥ million) 5,636 3,832 △32.0 Net income attributable to owners of the parent (¥ million) 4,270 3,542 △17.0」

    For the first 3 quarters, revenue declined 12.1%, operating profit declined 44.9%, ordinary profit declined 32.0% and net income attributable to owners of the parent declined 17.0%.
  21. FY2020-Q2First-half revenue and profit decline continuedAnnual report

    「Revenue (¥ million) 35,665 31,548 △11.5 Operating profit (¥ million) 4,252 2,334 △45.1 Ordinary profit (¥ million) 4,693 2,857 △39.1 Net income attributable to owners of the parent (¥ million) 3,337 2,150 △35.6」

    For the first 2 quarters, revenue declined 11.5%, operating profit declined 45.1%, ordinary profit declined 39.1% and net income attributable to owners of the parent declined 35.6%.
  22. FY2020-Q1Quarterly revenue and profit declineAnnual report

    「Revenue (¥ million) 17,851 16,099 △9.8 Operating profit (¥ million) 2,984 2,061 △30.9 Ordinary profit (¥ million) 3,602 2,406 △33.2 Net income attributable to owners of the parent (¥ million) 2,741 2,012 △26.6」

    In the first quarter, revenue declined 9.8%, operating profit declined 30.9%, ordinary profit declined 33.2% and net income attributable to owners of the parent declined 26.6%.
  23. FY2019Annual revenue and profit declineAnnual report

    「Operating profit declined by ¥3,684 million, or 37.3%, from the previous fiscal year to ¥6,202 million. In non-operating income and expenses, expenses increased by ¥559 million from the previous fiscal year due in part to the recording of losses on valuation of securities and foreign exchange losses. Ordinary profit consequently declined by ¥4,244 million, or 37.2%, to ¥7,169 million.」

    Annual revenue declined 2.3%, operating profit declined 37.3%, ordinary profit declined 37.2% and net income attributable to owners of the parent declined 39.4%.
  24. FY2019-Q3Revenue down, operating profit down, ordinary profit downAnnual report

    「Revenue (¥ million) 56,790 55,255 △2.7 Operating profit (¥ million) 8,453 4,970 △41.2 Ordinary profit (¥ million) 10,229 5,636 △44.9 Net income attributable to owners of the parent (¥ million) 8,052 4,270 △47.0」

    For the first 3 quarters, revenue declined 2.7%, operating profit declined 41.2%, ordinary profit declined 44.9% and net income attributable to owners of the parent declined 47.0%, marking a shift from the profit growth trend seen in the same period of the previous year to profit decline.
  25. FY2019-Q2Lower sales, higher operating income and lower ordinary incomeAnnual report

    「Although revenue declined and the cost-of-sales ratio increased, operating profit increased due to a decrease in selling, general and administrative expenses, mainly research and development expenses. Ordinary profit declined due to the absence of the gains on valuation of securities recorded in the same period of the previous year, while net income attributable to owners of the parent declined due in part to lower gains on sales of investment securities.」

    Revenue declined 2.5% year on year and operating profit increased 3.3%, while ordinary profit declined 9.3% and net income attributable to owners of the parent declined 22.0%.
  26. FY2019-Q1Lower revenue, higher profitAnnual report

    「Although revenue declined and the cost-of-sales ratio increased, operating profit, ordinary profit and net income attributable to owners of the parent increased due in part to a decrease in selling, general and administrative expenses, mainly research and development expenses.」

    Revenue declined 5.3% year on year, while operating profit increased 64.6%, ordinary profit increased 46.4% and net income attributable to owners of the parent increased 30.4%.
  27. FY2018Annual revenue and profit growthAnnual report

    「Operating profit increased by ¥1,396 million, or 16.4%, from the previous fiscal year to ¥9,887 million. In non-operating income and expenses, ordinary profit increased by ¥1,776 million, or 18.4%, from the previous fiscal year to ¥11,414 million, due in part to an increase in gains on valuation of securities and a decline in foreign exchange losses.」

    Revenue increased 3.2% year on year, operating profit increased 16.4%, ordinary profit increased 18.4% and net income attributable to owners of the parent increased 17.1%, resulting in annual revenue and profit growth.
  28. FY2018-Q3Higher Revenue and ProfitAnnual report

    「Although selling, general and administrative expenses, mainly research and development expenses, increased, higher revenue and a lower cost-of-sales ratio, mainly due to a decline in revenue from other businesses, resulted in higher operating profit, ordinary profit and net income attributable to owners of the parent.」

    Revenue increased 4.0% year on year, operating profit increased 9.2%, ordinary profit increased 14.7% and net income attributable to owners of the parent increased 14.3%, marking a shift from the profit decline seen in the same period of the previous year to profit growth.
  29. FY2018-Q2Operating profit down, ordinary and net profit upAnnual report

    「Although revenue increased and the gross profit increased due to a lower cost-of-sales ratio, mainly because of a decline in revenue from other businesses, operating profit declined as selling, general and administrative expenses, mainly research and development expenses, increased. Ordinary profit and net income attributable to owners of the parent increased, due in part to gains on valuation of securities and gains on sales of investment securities.」

    Revenue increased 2.1% year on year and operating profit declined 7.9%, while ordinary profit increased 6.5% and net income attributable to owners of the parent increased 10.0%.
  30. FY2018-Q1Quarterly profit declineAnnual report

    「Revenue (¥ million) 19,156 18,846 △1.6 Operating profit (¥ million) 3,320 1,813 △45.4 Ordinary profit (¥ million) 3,540 2,460 △30.5 Net income attributable to owners of the parent (¥ million) 2,834 2,101 △25.9」

    Revenue declined 1.6% year on year in the quarter, while operating profit declined 45.4%, ordinary profit declined 30.5% and net income attributable to owners of the parent declined 25.9%.
  31. FY2017Annual profit declineAnnual report

    「Operating profit, ordinary profit and net income attributable to owners of the parent declined, as the cost-of-sales ratio increased and selling, general and administrative expenses, mainly selling expenses, rose.」

    Revenue increased 0.6% year on year, while operating profit declined 17.4%, ordinary profit declined 15.1% and net income attributable to owners of the parent declined 5.4%.
  32. FY2017-Q3RestatedAnnual report

    「Although revenue increased, operating profit, ordinary profit and net income attributable to owners of the parent declined, due to a higher cost-of-sales ratio and an increase in selling, general and administrative expenses, mainly research and development expenses.」

    Revenue increased 1.6% year on year, while operating profit declined 31.2%, ordinary profit declined 28.1% and net income attributable to owners of the parent declined 20.0%.
  33. FY2017-Q2First statedAnnual report

    「Although revenue increased, operating profit, ordinary profit and net income attributable to owners of the parent declined, due to a higher cost-of-sales ratio and an increase in selling, general and administrative expenses, mainly selling expenses.」

    Revenue increased 6.7% year on year, while operating profit declined 11.3%, ordinary profit declined 13.0% and net income attributable to owners of the parent declined 1.4%.
Moved together

"Enhancing and Strengthening a Product Portfolio with Distinctive Features and Competitive Advantages" moved the same way as this thread, in the same document, in 3 of its 37 moves.

333332★123456
  1. ★This thread
  2. 1Enhancing and Strengthening a Product Portfolio with Distinctive Features and Competitive Advantages3×
  3. 2Efficient Advancement of Clinical Trials for Development Programs and Early Approval3×
  4. 3Establishing a Competitive Advantage and Securing Sales in the Domestic Prescription Pharmaceutical Market3×
  5. 4Stable dividends and profit allocation in line with earnings3×
  6. 5Share Buybacks and Cancellations as Flexible Capital Policy Measures3×
  7. 6Promoting overseas expansion and stabilizing the overseas earnings base2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Kissei Pharmaceutical's next results are scheduled for 2026-11-04. Read the earnings preview It last moved in the Earnings of 2026-07-31: "Other".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Decline in Operating Income, Ordinary Income and Net Income Despite Higher Revenue | KISSEI PHARMACEUTICAL CO.,LTD. (4547) | Komori